Gratus Capital’s Ascendis Pharma A/S ASND Stock Holding History

Gratus Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$682K	Hold	5,000	–	–	0.03%	220
2024 Q1	$756K	Hold	5,000	–	–	0.03%	192
2023 Q4	$630K	Hold	5,000	–	–	0.04%	172
2023 Q3	$468K	Hold	5,000	–	–	0.03%	178
2023 Q2	$446K	Hold	5,000	–	–	0.03%	182
2023 Q1	$536K	Buy	+5,000	New	+$572K	0.04%	155

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gratus Capital's ASND Position: Q2 2024 in Review

Gratus Capital held its Ascendis Pharma A/S (ASND) position steady in Q2 2024 at 5,000 shares worth $682K. The position accounts for 0.03% of the portfolio, ranked #220.

Gratus Capital first reported a position in ASND in Q1 2023 and has held it in 6 quarters since. The position peaked at $756K in Q1 2024. 203 funds tracked by Wall St. Rank hold ASND as of Q2 2024.

Gratus Capital held 5,000 shares of Ascendis Pharma A/S worth $682K as of Q2 2024.
Gratus Capital left its Ascendis Pharma A/S share count unchanged in Q2 2024.
Ascendis Pharma A/S made up 0.03% of Gratus Capital's portfolio in Q2 2024, its #220 holding.
Gratus Capital first reported a position in Ascendis Pharma A/S in Q1 2023 and has held it in 6 quarters since.
Gratus Capital's Ascendis Pharma A/S position peaked at $756K in Q1 2024.
203 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2024.

Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.